Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

NCT07745361 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Castration-Resistant Prostate Cancer (CRPC)
Castration-Resistant Prostate Cancer
Prostate Cancer
Prostate Cancer (Adenocarcinoma)

Interventions

DRUG: Oral MRT-2359
DRUG: Apalutamide

Sponsor

Monte Rosa Therapeutics, Inc